Gain Therapeutics names Jeanette Weidner Vice President, Finance

Gain Therapeutics, Inc. disclosed in an SEC filing that it appointed Jeanette Weidner as its Vice President, Finance, effective October 28, 2026.¹ In the role, Weidner will also serve as the company's principal financial officer and principal accounting officer.¹

According to the filing, Weidner, 44, brings 18 years of combined accounting and finance experience, with more than ten years in life sciences work across medical devices, regenerative medicine, and biopharmaceuticals.¹ Before joining Gain, she worked as a financial consultant for Senseonics Holdings Inc. (Nasdaq: SENS), a medical technology company that makes continuous glucose monitoring products, from March 2025 to October 2026¹, where she focused on financial reporting and operational accounting.¹ Earlier, she served as Vice President, Finance for OncoC4, Inc., a private, late-stage clinical biopharmaceutical company developing novel biologics for potential cancer treatment, from March 2021 to January 2025¹, where she built the accounting and finance function from the company's founding through its Phase III trials.¹

Under her employment agreement, also effective October 28, 2026, Weidner will receive an annual base salary of $275,000 and is eligible for an annual cash bonus initially targeted at 35% of that salary.¹ The company will also grant her an option to purchase up to 130,000 shares of common stock under the 2022 Equity Incentive Plan, priced at fair market value on the grant date and vesting over four years, with 25% vesting after one year and the rest vesting monthly thereafter.¹

Severance terms call for six months of base salary if she is terminated without cause after three months of employment, resigns for good reason, or her employment ends due to death or disability¹, with enhanced terms, including twelve months of salary and full acceleration of unvested stock awards, if termination occurs around a change of control.¹